2. Academic Validation
  3. Small-molecule polymerase inhibitor protects non-human primates from measles and reduces shedding

Small-molecule polymerase inhibitor protects non-human primates from measles and reduces shedding

  • Nat Commun. 2021 Sep 2;12(1):5233. doi: 10.1038/s41467-021-25497-4.
Kevin Wittwer 1,  Danielle E Anderson 2,  Kristin Pfeffermann 1,  Robert M Cox 3,  Josef D Wolf 3,  Sabine Santibanez 4,  Annette Mankertz 4,  Roland Plesker 1,  Zachary M Sticher 5,  Alexander A Kolkykhalov 5,  Michael G Natchus 5,  Christian K Pfaller 6,  Richard K Plemper 7,  Veronika von Messling 1 8
Affiliations

Affiliations

  • 1 Veterinary Medicine Division, Paul-Ehrlich-Institute, Langen, Germany.
  • 2 Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore.
  • 3 Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA.
  • 4 WHO European Regional Reference Laboratory for Measles and Rubella, Robert Koch-Institute, Berlin, Germany.
  • 5 Emory Institute for Drug Development, Emory University, Atlanta, GA, USA.
  • 6 Veterinary Medicine Division, Paul-Ehrlich-Institute, Langen, Germany. Christian.Pfaller@pei.de.
  • 7 Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA. rplemper@gsu.edu.
  • 8 Life Sciences Unit, Federal Ministry of Education and Research, Berlin, Germany.
PMID: 34475387 DOI: 10.1038/s41467-021-25497-4
Abstract

Measles virus (MeV) is a highly contagious pathogen that enters the human host via the respiratory route. Besides acute pathologies including fever, cough and the characteristic measles rash, the Infection of lymphocytes leads to substantial immunosuppression that can exacerbate the outcome of infections with additional pathogens. Despite the availability of effective vaccine prophylaxis, measles outbreaks continue to occur worldwide. We demonstrate that prophylactic and post-exposure therapeutic treatment with an orally bioavailable small-molecule polymerase inhibitor, ERDRP-0519, prevents measles disease in squirrel monkeys (Saimiri sciureus). Treatment initiation at the onset of clinical signs reduced virus shedding, which may support outbreak control. Results show that this clinical candidate has the potential to alleviate clinical measles and augment measles virus eradication.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-102074
    99.90%, MeV Polymerase Inhibitor